Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Titel:
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Auteur:
Ryan, Charles J Smith, Matthew R Fizazi, Karim Saad, Fred Mulders, Peter F A Sternberg, Cora N Miller, Kurt Logothetis, Christopher J Shore, Neal D Small, Eric J Carles, Joan Flaig, Thomas W Taplin, Mary-Ellen Higano, Celestia S de Souza, Paul de Bono, Johann S Griffin, Thomas W De Porre, Peter Yu, Margaret K Park, Youn C Li, Jinhui Kheoh, Thian Naini, Vahid Molina, Arturo Rathkopf, Dana E